EPIRUS Biopharmaceuticals, Inc.

Equities

EPRSQ

US29428P1075

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2018	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
2018	Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	CI

EPIRUS Biopharmaceuticals, Inc. Launches its First Product Infimab in India

December 02, 2014 at 08:00 am EST

EPIRUS Biopharmaceuticals, Inc. announced the launch of its first product, Infimab (BOW015), the first infliximab biosimilar in India. Infimab, a Remicade (infliximab) biosimilar, is being launched in cooperation with EPIRUS' commercialization partner Ranbaxy Laboratories Limited (Ranbaxy). Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai.

Latest news about EPIRUS Biopharmaceuticals, Inc.

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	18-10-09	CI
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	18-01-30	CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	18-01-19	CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18-01-17	CI
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	17-12-11	CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	16-09-19	CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	16-08-05	CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	16-08-03	CI
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	16-07-25	CI
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	16-07-25	CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	16-07-01	CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	16-06-29	CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	16-06-13	CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes	16-05-09	CI
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	16-03-28	CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016	16-03-15
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-15	CI
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	16-02-09	CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015	15-11-16
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	15-11-16	CI
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-16	CI
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer	15-11-10	CI
Taro Pharmaceuticals Inc. acquired Zalicus Pharmaceuticals Ltd. from EPIRUS Biopharmaceuticals, Inc. for CAD 60.3 million.	15-10-06	CI
EPIRUS Biopharmaceuticals, Inc. acquired Bioceros B.V.	15-09-08	CI
Transcript : EPIRUS Biopharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 01:20 PM	15-08-11

Chart EPIRUS Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

EPIRUS Biopharmaceuticals, Inc. is in bankruptcy.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EPIRUS BIOPHARMACEUTICALS, INC.	-.--%	26
MODERNA, INC.	+44.21%	56.65B
IQVIA HOLDINGS INC.	-6.89%	39.44B
LONZA GROUP AG	+39.24%	39.03B
CELLTRION, INC.	-11.17%	26.86B
ICON PUBLIC LIMITED COMPANY	+12.60%	26.75B
ALNYLAM PHARMACEUTICALS, INC.	-21.92%	19.03B
BIO-TECHNE CORPORATION	+1.41%	12.28B
UNITED THERAPEUTICS CORPORATION	+24.40%	12.26B
MEDPACE HOLDINGS, INC.	+27.51%	12.04B

Other Biotechnology & Medical Research